X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/24/2869078/0/en/Erasca-Announces-Three-Presentations-at-the-2024-ASCO-Annual-Meeting.html
https://www.prnewswire.com/news-releases/european-medicines-agency-validates-pierre-fabre-laboratories-marketing-authorisation-application-for-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-brafv600-mutant-advanced-non-small-cell-lung-c-301975614.html
https://www.onclive.com/view/encorafenib-binimetinib-combo-highlights-novel-therapies-for-braf-v600-nsclc
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217404
https://www.globenewswire.com//news-release/2022/11/30/2564908/0/en/Erasca-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Pierre-Fabre-to-Evaluate-ERAS-007-and-Encorafenib-Combination.html
https://www.clinicaltrialsarena.com/news/pfizer-strata-partnership-cancer-trial/
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-encorafenib-capsules-1659342795.pdf
https://www.pmlive.com/pharma_news/eortc_and_pierre_fabre_launch_phase_3_trial_for_melanoma_1449323
https://www.eortc.org/blog/2022/05/24/pierre-fabre-and-eortc-open-a-large-phase-iii-clinical-study-in-the-adjuvant-setting-of-stage-iib-c-melanoma/
https://www.globenewswire.com/news-release/2021/09/08/2293365/0/en/Erasca-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Pfizer-to-Evaluate-ERAS-007-and-Encorafenib-Combination.html
https://www.ono-pharma.com/sites/default/files/en/news/press/enews20210820.pdf
http://www.pharmatimes.com/news/nice_backs_braftovi_for_braf-positive_colorectal_cancer_1357546
https://pharmaphorum.com/news/nice-says-yes-to-braftovi-combination-for-colorectal-cancer/
https://investors.pfizer.com/investor-news/press-release-details/2020/New-Data-from-18-Approved-and-Investigational-Pfizer-Medicines-to-be-Showcased-at-ASCO20-Virtual-Scientific-Program/default.aspx
https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_braftovi_encorafenib_in_combination_with_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer_crc_after_prior_therapy
http://www.pharmatimes.com/news/ema_validates_bratovi,_mektovi_application_for_some_mcrc_1315939
http://www.pharmatimes.com/news/hse_reimburses_braftovi_combo_1298971
http://www.pharmafile.com/news/524241/pierre-fabres-triplet-therapy-makes-strong-showing-braf-v600e-mutant-metastatic-colorect
http://www.pharmatimes.com/news/darzalex,_ibrance_among_latest_smc_decisions_1294142
https://www.biospace.com/article/array-biopharma-s-triple-drug-combo-could-be-gamechanger-for-colorectal-cancer/
https://www.businesswire.com/news/home/20190706005001/en/Pierre-Fabre-partner-Array-BioPharma-announce-interim
https://www.fiercepharma.com/pharma/array-played-pfizer-s-eagerness-to-land-a-deal-time-and-got-itself-a-better-offer
https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b
https://endpts.com/right-back-at-you-pfizer-beigene-and-a-pfizer-spinout-launch-a-newco-to-develop-a-mek-braf-inhibitor-that-could-rival-11-4b-combo/
https://www.prnewswire.com/news-releases/array-biopharma-announces-presentation-of-updated-overall-survival-from-the-phase-3-columbus-trial-of-braftovi--mektovi-in-advanced-brafmutant-melanoma-at-2019-asco-annual-meeting-300858355.html
https://www.reuters.com/article/us-array-biopharma-study/array-biopharmas-colorectal-cancer-combo-treatment-meets-main-goals-idUSKCN1SR1AE
http://www.pharmafile.com/news/522388/array-biopharmas-braftovi-triple-therapy-meets-both-endpoints-advanced-colorectal-cancer
https://www.prnewswire.com/news-releases/braftovi-encorafenib-in-combination-with-mektovi-binimetinib-and-erbitux-cetuximab-or-panitumumab-recommended-by-the-national-comprehensive-cancer-network-nccn-guidelines-as-a-treatment-option-for-patients-with-advance-300813829.html
http://www.pharmafile.com/news/519891/nice-recommends-pierre-fabres-braftovi-braf-v600-mutated-advanced-melanoma
http://www.pharmatimes.com/news/nice_ok_for_bravtovi_skin_cancer_drug_1275652
https://www.ema.europa.eu/documents/product-information/braftovi-epar-product-information_en.pdf
http://www.pharmatimes.com/news/eu_approves_new_option_for_metastatic_melanoma_1253166
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002994.jsp&mid=WC0b01ac058004d5c1
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004580/smops/Positive/human_smop_001347.jsp&mid=WC0b01ac058001d127
https://www.businesswire.com/news/home/20180604005578/en/Pierre-Fabre-Partner-Array-BioPharma-Announce-Additional
Market Place
Share 
